Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The herpesvirus envelope glycoprotein-heparan sulfate proteoglycan interface is the primary site for the initial attachment of herpesviruses, such as Herpes Simplex Virus (HSV), to host cells. This interaction typically involves viral glycoproteins gC and gB binding to the glycosaminoglycan chains of host cell surface heparan sulfate proteoglycans (HSPGs) [1][2]. This tethering step is crucial for concentrating the virus on the cell surface and facilitating subsequent interactions with entry receptors like nectin-1 or HVEM, leading to membrane fusion [3]. Because this interface is essential for the initiation of infection, it serves as a significant therapeutic target for entry inhibitors [4]. Drugs targeting this interface, such as heparin mimetics or polyanionic compounds, work by competitively binding to the viral glycoproteins, thereby preventing the virus from docking onto the host cell [5].
Competitive inhibition of viral attachment to host cell surface heparan sulfate proteoglycans.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpesvirus envelope glycoprotein-heparan sulfate proteoglycan interface (HSV gB/gC-HSPG interface).